Scholarlink

Background <p>Urine-based liquid biopsy enables non-invasive, repeat sampling in urologic cancers, yet evidence remains fragmented across diseases, analytes, and platforms. We mapped the research landscape and clinically framed thematic trajectories of the field.</p> Methods <p>English-language articles and reviews (2015–2025) were retrieved from WoSCC (SCIE) using urologic cancer terms combined with urine/urinary and “liquid biopsy”. CiteSpace, VOSviewer and bibliometrix were used to map collaboration, co-citation, citation bursts and keyword evolution. Robustness was assessed via sensitivity analyses and matched PubMed validation.</p> Results <p>Among 431 publications from 51 countries, output rose steadily and accelerated in 2021. Co-citation and citation-burst analyses suggested a shift from feasibility-oriented method expansion to standardization-oriented, platform-integrative synthesis. Collaboration showed a Europe–North America core with growing East Asian participation. Keywords converged on two clinical streams: prostate cancer diagnostics (urinary RNA/exosome panels and multivariable models for biopsy decision-making) and urothelial cancer monitoring (mutation/methylation assays and enhanced cytology for surveillance and potential cystoscopy de-escalation). Evidence for renal cell carcinoma and rarer urologic cancers remained sparse and largely exploratory, including methylation profiling, extracellular vesicles (EVs) and metabolomics.</p> Conclusions <p>This bibliometric evidence map delineates disease-specific trajectories and gaps to inform future validation priorities. Bibliometrics reflect research attention, not proven clinical utility.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

From feasibility to translational pathways: a bibliometric and knowledge-mapping analysis of urine-based liquid biopsy in urologic cancers (2015–2025)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月25日

查看全文
  • Hanlin Liu,
  • Yuqiang Fu,
  • Jianwei Yang,
  • Li Wang,
  • Junsheng Bao,
  • Liyun Ding,
  • Wei Shi,
  • Siyu Chen,
  • Xiaoran Li

摘要

Background

Urine-based liquid biopsy enables non-invasive, repeat sampling in urologic cancers, yet evidence remains fragmented across diseases, analytes, and platforms. We mapped the research landscape and clinically framed thematic trajectories of the field.

Methods

English-language articles and reviews (2015–2025) were retrieved from WoSCC (SCIE) using urologic cancer terms combined with urine/urinary and “liquid biopsy”. CiteSpace, VOSviewer and bibliometrix were used to map collaboration, co-citation, citation bursts and keyword evolution. Robustness was assessed via sensitivity analyses and matched PubMed validation.

Results

Among 431 publications from 51 countries, output rose steadily and accelerated in 2021. Co-citation and citation-burst analyses suggested a shift from feasibility-oriented method expansion to standardization-oriented, platform-integrative synthesis. Collaboration showed a Europe–North America core with growing East Asian participation. Keywords converged on two clinical streams: prostate cancer diagnostics (urinary RNA/exosome panels and multivariable models for biopsy decision-making) and urothelial cancer monitoring (mutation/methylation assays and enhanced cytology for surveillance and potential cystoscopy de-escalation). Evidence for renal cell carcinoma and rarer urologic cancers remained sparse and largely exploratory, including methylation profiling, extracellular vesicles (EVs) and metabolomics.

Conclusions

This bibliometric evidence map delineates disease-specific trajectories and gaps to inform future validation priorities. Bibliometrics reflect research attention, not proven clinical utility.